Telix Pharmaceuticals Securities Class Action Launched with Lead Plaintiff Deadline on January 9, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6d ago
0mins
Source: Globenewswire
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Telix Pharmaceuticals securities between February 21 and August 28, 2025, that the lead plaintiff deadline is January 9, 2026, allowing potential compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Telix made materially false statements during the class period, overstating the progress of its prostate cancer therapeutic candidates and the quality of its supply chain, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its successful track record and extensive experience in this field.
- Investor Guidance: Investors are encouraged to select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure they receive the best representation and support in the class action.
TLX
$8.09+Infinity%1D
Analyst Views on TLX
About TLX
Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its segments include Therapeutics, Precision Medicine and Telix Manufacturing Solutions. Therapeutics segment develops targeted radionuclide therapies for urologic, neurologic, musculoskeletal and hematological cancers. Precision Medicine segment focuses on bringing diagnostic imaging solutions to market. Precision Medicine segment also includes MedTech and International businesses. Telix Manufacturing Solutions segment is its global network of facilities designed to deliver patient doses worldwide. Its pipeline products include TLX591, TLX250, TLX101, TLX66, TLX592, TLX252, TLX400, Illuccix (68Ga-PSMA-11) and TLX007-CDx.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
